Otonomy, Inc. Logo
Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus
August 01, 2022 07:30 ET | Otonomy, Inc.
OTO-313 demonstrated no clinically meaningful improvement versus placebo for primary and secondary endpoints across all timepointsCompany to discontinue development of OTO-313 and implement other...
Otonomy, Inc. Logo
Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update
July 25, 2022 16:05 ET | Otonomy, Inc.
Top-line results for OTO-313 Phase 2 trial in tinnitus expected in August 2022; patient enrollment completed for clinical safety evaluation of higher and bilateral dosing of OTO-313 with top-line...
Otonomy, Inc. Logo
Otonomy to Host Virtual Investor R&D Event on March 22, 2022
March 15, 2022 07:30 ET | Otonomy, Inc.
SAN DIEGO, March 15, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy, Inc. Logo
Otonomy Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
February 28, 2022 16:27 ET | Otonomy, Inc.
OTO-313 Phase 2 trial in tinnitus fully enrolled ahead of schedule with top-line results expected in mid-2022; initiating safety evaluation of higher and bilateral dosingOTO-413 Phase 2a cohort in...
Otonomy, Inc. Logo
Otonomy Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in Tinnitus
February 22, 2022 07:30 ET | Otonomy, Inc.
OTO-313 Phase 2 trial is fully enrolled ahead of scheduleTop-line results for all timepoints expected in mid-2022 SAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a...
Otonomy, Inc. Logo
Otonomy Reports Corporate and Product Pipeline Update
January 06, 2022 07:51 ET | Otonomy, Inc.
Multiple clinical trial readouts for OTO-313 in tinnitus and OTO-413 in hearing loss expected during 2022 Current capital funds operations into second half of 2023 SAN DIEGO, Jan. 06, 2022 (GLOBE...
Otonomy, Inc. Logo
Otonomy Announces Publication of Phase 1/2 Trial Results Showing Tinnitus Improvement in Patients Receiving OTO-313
October 12, 2021 07:30 ET | Otonomy, Inc.
Results published in Otology & Neurotology, a leading journal in fieldOTO-313 was well-tolerated and demonstrated a statistically significant higher proportion of responders than placebo across...
Otonomy, Inc. Logo
Otonomy Announces Presentation of OTO-313 Clinical Results at American Neurotology Society Annual Meeting
April 05, 2021 07:30 ET | Otonomy, Inc.
SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy, Inc. Logo
Otonomy Initiates Phase 2 Clinical Trial of OTO-313 in Tinnitus
March 25, 2021 07:30 ET | Otonomy, Inc.
Phase 2 study design based on successful Phase 1/2 trial including use of Tinnitus Functional Index (TFI) responder analysis for primary efficacy endpointPatient enrollment criteria refined to enrich...
Otonomy, Inc. Logo
Otonomy to Participate in Three Upcoming Investor Conferences
February 25, 2021 07:30 ET | Otonomy, Inc.
SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...